Jazz Pharmaceuticals PLCNASDAQ:JAZZ
- LAST PRICE160.4400
- TODAY'S CHANGE (%)0.4000 (0.2499%)
- Bid / Lots154.2500/ 1
- Ask / Lots163.0000/ 1
- Open / Previous Close159.8500 / 160.0400
- Day Range
- 52 Week Range
- Volume381,540
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | JAZZ |
|---|---|---|
| 09:32 ET | 7317 | 159.78 |
| 09:34 ET | 300 | 160.45 |
| 09:36 ET | 200 | 160.29 |
| 09:38 ET | 5500 | 160.085 |
| 09:39 ET | 100 | 160.11 |
| 09:41 ET | 1400 | 159.28 |
| 09:43 ET | 1598 | 159.33 |
| 09:45 ET | 100 | 159.65 |
| 09:48 ET | 1600 | 159.01 |
| 09:50 ET | 2603 | 158.86 |
| 09:52 ET | 600 | 158.71 |
| 09:54 ET | 100 | 158.57 |
| 09:56 ET | 100 | 158.4125 |
| 09:57 ET | 500 | 158.81 |
| 09:59 ET | 300 | 158.91 |
| 10:01 ET | 200 | 158.965 |
| 10:03 ET | 1100 | 158.965 |
| 10:06 ET | 5700 | 159.06 |
| 10:08 ET | 2092 | 159.725 |
| 10:10 ET | 200 | 159.645 |
| 10:12 ET | 1200 | 159.54 |
| 10:14 ET | 200 | 159.455 |
| 10:15 ET | 100 | 159 |
| 10:17 ET | 1000 | 158.72 |
| 10:19 ET | 200 | 159.08 |
| 10:21 ET | 300 | 159.37 |
| 10:24 ET | 500 | 159.62 |
| 10:26 ET | 200 | 159.6 |
| 10:28 ET | 1382 | 159.53 |
| 10:30 ET | 100 | 159.57 |
| 10:32 ET | 1400 | 159.76 |
| 10:35 ET | 300 | 159.37 |
| 10:39 ET | 300 | 159.54 |
| 10:42 ET | 300 | 159.41 |
| 10:44 ET | 705 | 159.48 |
| 10:48 ET | 500 | 159.46 |
| 10:50 ET | 100 | 159.235 |
| 10:53 ET | 400 | 158.945 |
| 10:55 ET | 500 | 158.8 |
| 10:57 ET | 300 | 158.65 |
| 11:02 ET | 1000 | 158.34 |
| 11:04 ET | 552 | 157.47 |
| 11:06 ET | 1605 | 157.47 |
| 11:08 ET | 1000 | 157.77 |
| 11:09 ET | 400 | 157.78 |
| 11:13 ET | 200 | 158.04 |
| 11:22 ET | 500 | 158.52 |
| 11:24 ET | 300 | 158.46 |
| 11:26 ET | 200 | 158.54 |
| 11:27 ET | 200 | 158.49 |
| 11:31 ET | 500 | 158.44 |
| 11:33 ET | 400 | 158.46 |
| 11:36 ET | 100 | 158.685 |
| 11:38 ET | 605 | 158.99 |
| 11:40 ET | 100 | 159.03 |
| 11:42 ET | 1500 | 158.725 |
| 11:44 ET | 900 | 158.79 |
| 11:45 ET | 200 | 158.74 |
| 11:47 ET | 316 | 159.06 |
| 11:49 ET | 400 | 159.165 |
| 11:51 ET | 200 | 159.1401 |
| 11:54 ET | 300 | 159.07 |
| 11:58 ET | 1000 | 159.1 |
| 12:02 ET | 100 | 159.07 |
| 12:03 ET | 100 | 159.125 |
| 12:05 ET | 600 | 158.83 |
| 12:07 ET | 300 | 159.08 |
| 12:09 ET | 819 | 158.82 |
| 12:14 ET | 1100 | 159.21 |
| 12:16 ET | 200 | 159.18 |
| 12:18 ET | 100 | 159.225 |
| 12:20 ET | 100 | 159.15 |
| 12:21 ET | 200 | 159.08 |
| 12:25 ET | 700 | 158.92 |
| 12:30 ET | 400 | 158.855 |
| 12:32 ET | 1300 | 159.135 |
| 12:34 ET | 500 | 159.13 |
| 12:36 ET | 600 | 159.39 |
| 12:38 ET | 1264 | 159.35 |
| 12:39 ET | 100 | 159.24 |
| 12:43 ET | 500 | 159.29 |
| 12:48 ET | 500 | 159.24 |
| 12:50 ET | 300 | 159.24 |
| 12:52 ET | 660 | 159.2 |
| 12:54 ET | 200 | 159.14 |
| 12:56 ET | 498 | 159.16 |
| 12:57 ET | 300 | 159.18 |
| 01:01 ET | 258 | 159.195 |
| 01:03 ET | 898 | 159.36 |
| 01:06 ET | 800 | 159.34 |
| 01:08 ET | 600 | 159.38 |
| 01:10 ET | 3180 | 159.14 |
| 01:14 ET | 500 | 158.99 |
| 01:15 ET | 995 | 159.005 |
| 01:17 ET | 200 | 158.87 |
| 01:24 ET | 108 | 158.8844 |
| 01:26 ET | 500 | 158.745 |
| 01:28 ET | 496 | 158.79 |
| 01:30 ET | 200 | 158.87 |
| 01:33 ET | 638 | 158.905 |
| 01:35 ET | 200 | 158.875 |
| 01:37 ET | 2200 | 159.33 |
| 01:42 ET | 100 | 159.28 |
| 01:44 ET | 840 | 159.35 |
| 01:46 ET | 1900 | 159.34 |
| 01:48 ET | 200 | 159.355 |
| 01:50 ET | 300 | 159.41 |
| 01:51 ET | 300 | 159.46 |
| 01:57 ET | 100 | 159.46 |
| 02:00 ET | 600 | 159.58 |
| 02:02 ET | 1679 | 159.45 |
| 02:04 ET | 1400 | 159.745 |
| 02:06 ET | 600 | 159.715 |
| 02:08 ET | 499 | 159.83 |
| 02:09 ET | 1212 | 159.84 |
| 02:11 ET | 2600 | 159.48 |
| 02:13 ET | 1200 | 159.76 |
| 02:15 ET | 1218 | 159.41 |
| 02:18 ET | 1200 | 159.5 |
| 02:20 ET | 500 | 159.41 |
| 02:22 ET | 1500 | 159.59 |
| 02:24 ET | 1700 | 159.365 |
| 02:26 ET | 300 | 159.31 |
| 02:27 ET | 3002 | 159.535 |
| 02:29 ET | 2339 | 159.67 |
| 02:31 ET | 703 | 159.785 |
| 02:33 ET | 6696 | 160.36 |
| 02:36 ET | 5540 | 160.55 |
| 02:38 ET | 900 | 160.375 |
| 02:40 ET | 1125 | 160.27 |
| 02:42 ET | 1200 | 160.6 |
| 02:44 ET | 400 | 160.46 |
| 02:45 ET | 710 | 160.465 |
| 02:47 ET | 900 | 160.45 |
| 02:49 ET | 100 | 160.265 |
| 02:51 ET | 700 | 160.18 |
| 02:56 ET | 1375 | 160.27 |
| 02:58 ET | 400 | 160.05 |
| 03:00 ET | 1824 | 160.28 |
| 03:02 ET | 900 | 160.18 |
| 03:03 ET | 1100 | 159.94 |
| 03:05 ET | 4788 | 160.3 |
| 03:07 ET | 2146 | 160.3598 |
| 03:09 ET | 890 | 160.265 |
| 03:12 ET | 300 | 160.39 |
| 03:14 ET | 200 | 160.255 |
| 03:16 ET | 700 | 160.285 |
| 03:18 ET | 900 | 160.42 |
| 03:20 ET | 465 | 160.5 |
| 03:21 ET | 997 | 160.43 |
| 03:23 ET | 1036 | 160.5 |
| 03:25 ET | 200 | 160.56 |
| 03:27 ET | 500 | 160.48 |
| 03:30 ET | 800 | 160.5 |
| 03:32 ET | 577 | 160.3093 |
| 03:34 ET | 14230 | 161.05 |
| 03:36 ET | 9022 | 161.05 |
| 03:38 ET | 7496 | 160.93 |
| 03:39 ET | 400 | 160.665 |
| 03:41 ET | 500 | 160.53 |
| 03:45 ET | 739 | 160.505 |
| 03:48 ET | 300 | 160.48 |
| 03:50 ET | 1200 | 160.34 |
| 03:52 ET | 1407 | 159.92 |
| 03:54 ET | 2901 | 160.15 |
| 03:56 ET | 3637 | 160.265 |
| 03:57 ET | 7676 | 160.44 |
| 03:59 ET | 7462 | 160.44 |
Jun 29, 2022
Insider Sell: Jazz Pharmaceuticals, from 6:05PM ET on Wednesday Jun 29, 2022 by MT Newswires
6:05PM ET on Wednesday Jun 29, 2022 by MT Newswires
Jun 28, 2022
Jazz Pharmaceuticals Says First of Phase 3 Trials of Cannabis-Based Multiple Sclerosis Drug Didn't Meet Primary Endpoint, from 8:17AM ET on Tuesday Jun 28, 2022 by MT Newswires
8:17AM ET on Tuesday Jun 28, 2022 by MT NewswiresBRIEF-Jazz Pharmaceuticals Announces Top-Line Results From Phase 3 Trial Evaluating Nabiximols Oromucosal Spray In Adult Participants With Multiple Sclerosis Spasticity, from 7:37AM ET on Tuesday Jun 28, 2022 by Thomson Reuters
7:37AM ET on Tuesday Jun 28, 2022 by Thomson ReutersJazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity, from 7:30AM ET on Tuesday Jun 28, 2022 by PR Newswire
7:30AM ET on Tuesday Jun 28, 2022 by PR Newswire
Jun 14, 2022
BUZZ-U.S. STOCKS ON THE MOVE-SeaChange International, Revlon, FedEx , from 2:12PM ET on Tuesday Jun 14, 2022 by Thomson Reuters
2:12PM ET on Tuesday Jun 14, 2022 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Jazz Pharmaceuticals PLC | 10.0B | -21.3x | --- |
Incyte Corp | 17.6B | 19.0x | +51.40% |
Perrigo Company PLC | 5.5B | -40.3x | --- |
Horizon Therapeutics PLC | 19.0B | 22.6x | --- |
Endo International PLC | 122.3M | -0.2x | --- |
Catalent Inc | 19.0B | 39.3x | +28.57% |
Company Information
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
Contact Information
- Headquarters
- Fifth Fl Waterloo Exchange, Waterloo RoadDUBLIN, Ireland 4
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Bruce Cozadd
- President
- Daniel Swisher
- Chief Financial Officer, Executive Vice President
- Renee Gala
- Chief Operating Officer, Executive Vice President, Managing Director, Europe and International
- Christopher Tovey
- Executive Vice President, General Manager, North America
- Kimberly Sablich
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.0B |
|---|---|
Revenue (TTM) | $3.3B |
Shares Outstanding | 62.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.73 |
EPS | $-7.52 |
Book Value | $64.34 |
P/E Ratio | -21.3x |
Price/Sales (TTM) | 3.0 |
Price/Cash Flow (TTM) | 45.7x |
Operating Margin | 2.90% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
